NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present a […]

New York and London, October 25, 2019 –Stellex Capital Management (“Stellex”), a middle market private equity firm with offices in New York and London, announced today that it has completed the sale of Morbark, LLC (“Morbark” or the “Company”), a […]

New York and London, October 25, 2019 –Stellex Capital Management (“Stellex”), a middle market private equity firm with offices in New York and London, announced today that it has completed the sale of Morbark, LLC (“Morbark” or the “Company”), a […]

  Transaction expected to close in 4Q 2019   New York and London, September 12, 2019 –Stellex Capital Management(“Stellex”), a middle market private equity firm with offices in New York and London, announced today it has entered into an agreement […]

Advancement of Nalbuphine ER Through Clinical Development in Multiple Indications New Haven, CT, August 12, 2019– Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions,today […]

Schools remain highly vulnerable with legacy security infrastructure and require significant upgrades to ensure the safety and well-being of staff and students   New York, July 24, 2019– Post Capital Partnerstoday announced that it has completed a recapitalization of IntraLogic […]